Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Transcode Therapeutics, Inc., Boston, MA, USA;
Dr. Medarova is Chief Technology Officer at TransCode Therapeutics, Inc. Dr. Medarova carried out seminal work in the field of RNA oncology. Together with her colleagues at Harvard Medical School, she advanced research validating microRNAs as therapeutic targets and diagnostic biomarkers in cancer. Her work generated substantial interest in the research community since it illustrated the value of nanotechnology for delivering RNA therapy for oncology applications and described approaches for the noninvasive monitoring of RNA delivery. Since then, Dr. Medarova has emerged as one of the leaders in the field of non-coding RNA delivery to cancer. She has developed a robust NIH-funded program and authored multiple high-impact publications on the topic of RNA delivery, nanotechnology, and the biology of cancer metastasis. Dr. Medarova obtained a B.A. in pre-medicine from the University of Southern Maine and a Ph.D. in Genetics from the University of New Hampshire.